LAG-3清除性单克隆抗体GSK2831781治疗活动性溃疡性结肠炎的随机双盲安慰剂对照研究
本研究为随机双盲安慰剂对照研究,纳入中重度活动性溃疡性结肠炎患者,评估GSK2831781的安全性、耐受性、疗效、药代动力学和药效学。 interim分析显示疗效无效标准已满足,研究提前终止(NCT03893565)。GSK2831781 450 mg静脉给药组与安慰剂组完全Mayo评分中位变化相似,内镜改善应答率偏向安慰剂,临床缓解率相似;血液中LAG-3+细胞耗竭至基线的51%,但结肠黏膜中LAG-3+细胞无减少。
要点
- GSK2831781 450 mg IV组与安慰剂组完全Mayo评分中位变化相似(-1.4 vs -1.4)。
- 内镜改善应答率偏向安慰剂,临床缓解率两组相似。
- 450 mg IV组14例(29%)发生UC不良事件,安慰剂组1例(4%)。
核心结论
- 尽管血液中靶细胞耗竭,GSK2831781未能减轻结肠黏膜炎症,提示无药理学效应;研究提前终止(NCT03893565)。
研究设计与样本
- 随机、双盲、安慰剂对照研究,纳入中重度活动性溃疡性结肠炎患者,评估GSK2831781的安全性、耐受性、疗效、药代动力学和药效学。
- 所有剂量水平共随机104例参与者,在 interim分析显示疗效无效标准已满足之前;疗效结果聚焦双盲诱导期(GSK2831781 450 mg IV,N=48;安慰剂,N=27)。
主要发现
- 完全Mayo评分较基线中位变化(95%可信区间[CrI])两组相似:GSK2831781 450 mg IV组-1.4 [-2.2, -0.7];安慰剂组-1.4 [-2.4, -0.5]。
- 内镜改善应答率偏向安慰剂;临床缓解率两组相似。
- 450 mg IV组14例(29%)参与者发生UC不良事件,安慰剂组1例(4%)。
- 血液中LAG-3+细胞耗竭至基线的51%;但结肠黏膜中LAG-3+细胞无减少。
- 结肠活检转录组分析显示两组间无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究提前终止(NCT03893565)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selective depletion of T cells expressing LAG-3, an immune checkpoint receptor that is upregulated on activated T cells, has been investigated in pre-clinical models as a potential therapeutic approach in inflammatory and autoimmune diseases where activated T cells are implicated. AIMS: GSK2831781, a depleting monoclonal antibody that specifically binds LAG-3 proteins, may deplete activated LAG-3+ cells in ulcerative colitis (UC). METHODS: Patients with moderate to severe UC were randomised to GSK2831781 or placebo. Safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK2831781 were evaluated. RESULTS: One hundred four participants across all dose levels were randomised prior to an interim analysis indicating efficacy futility criteria had been met. Efficacy results focus on the double-blind induction phase of the study (GSK2831781 450 mg intravenously [IV], N = 48; placebo, N = 27). Median change from baseline (95% credible interval [CrI]) in complete Mayo score was similar between groups (GSK2831781 450 mg IV: -1.4 [-2.2, -0.7]; placebo: -1.4 [-2.4, -0.5]). Response rates for endoscopic improvement favoured placebo. Clinical remission rates were similar between groups. In the 450-mg IV group, 14 (29%) participants had an adverse event of UC versus 1 (4%) with placebo. LAG-3+ cells were depleted to 51% of baseline in blood; however, there was no reduction in LAG-3+ cells in the colonic mucosa. Transcriptomic analysis of colon biopsies showed no difference between groups. CONCLUSION: Despite evidence of target cell depletion in blood, GSK2831781 failed to reduce inflammation in the colonic mucosa suggesting no pharmacological effect. The study was terminated early (NCT03893565).
引用
- D'Haens G, Peyrin-Biroulet L, Marks DJB, et al. A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis. Aliment Pharmacol Ther. 2023. PMID: 37323059. doi:10.1111/apt.17557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。